Goldman Sachs
CASC

Goldman Sachs’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Goldman Sachs’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-50,000
Closed -$528K – 7023
2013
Q4 		$528K Hold
50,000
– – ﹤0.01% 5255
2013
Q3 		$618K Hold
50,000
– – ﹤0.01% 4997
2013
Q2 		$471K Buy
+50,000
New +$642K ﹤0.01% 4988

Goldman Sachs's CASC Position: Q1 2018 in Review

Goldman Sachs sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 664,386 shares — an estimated $2.46M sold.

Goldman Sachs first reported a position in CASC in Q2 2013 and held it in 18 quarters. The position peaked at $2.46M in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Goldman Sachs reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Goldman Sachs sold 664,386 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2.46M.
  • Goldman Sachs first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
  • Goldman Sachs's Cascadian Therapeutics, Inc. position peaked at $2.46M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.